Trust Co. of Toledo NA OH Sells 5,638 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Trust Co. of Toledo NA OH decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 32.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,795 shares of the medical equipment provider’s stock after selling 5,638 shares during the period. Trust Co. of Toledo NA OH’s holdings in Zimmer Biomet were worth $1,061,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Key Financial Inc lifted its holdings in shares of Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. grew its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 116 shares during the last quarter. Root Financial Partners LLC purchased a new position in Zimmer Biomet during the 3rd quarter worth $31,000. Cary Street Partners Investment Advisory LLC increased its position in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 149 shares in the last quarter. Finally, Mather Group LLC. acquired a new position in Zimmer Biomet during the 3rd quarter valued at about $36,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.39% of the stock is owned by company insiders.

Zimmer Biomet Stock Down 0.1%

Shares of ZBH stock opened at $90.82 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The firm has a market capitalization of $17.58 billion, a PE ratio of 25.66, a P/E/G ratio of 1.86 and a beta of 0.61. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The stock’s 50-day simple moving average is $92.33 and its 200-day simple moving average is $93.66.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the previous year, the company posted $2.31 earnings per share. The company’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is 27.12%.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of research analyst reports. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Barclays decreased their price objective on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research report on Thursday, February 12th. UBS Group reiterated a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Weiss Ratings downgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, March 23rd. Finally, Robert W. Baird restated a “neutral” rating and set a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $106.20.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.